Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET
- PMID: 11748732
- DOI: 10.1002/mds.1212
Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET
Abstract
Studies of resting regional cerebral glucose consumption (rCMRGlc) in nondemented patients with Parkinson's disease (PD) have produced conflicting results, reporting both reduced and normal metabolism in advanced disease and reduced or normal metabolism after dopaminergic therapy. To investigate these issues, [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) was performed in 11 nondemented PD patients with advanced disease and 10 age-matched controls. PD patients were studied after withdrawal of all dopaminergic medication to produce a practically defined off condition, and a second time 1 hour after levodopa, resulting in a clinical on state. Dynamic PET scans and simultaneous arterialised venous blood samples of [(18)F] activity were obtained. A graphical approach was used to generate parametric images of rCMRGlc and statistical parametric mapping to localise significant metabolic changes in PD. Compared with controls, global rCMRGlc was reduced in the on but not in the off condition in PD. In both states, significant regional reductions of glucose uptake were found in the parietal, frontal, temporal cortex, and caudate nucleus. Reductions correlated with the severity of disability in frontal and temporal cortex. Direct comparison between on and off conditions revealed relatively greater reductions of uptake in the ventral/orbital frontal cortex and the thalamus during on. Results suggest that cortical and caudate hypometabolism are common in advanced PD and that caution is mandatory if [(18)F]FDG PET is being used to differentiate advanced PD from dementia and progressive supranuclear palsy where similar reductions are seen. Furthermore, in PD, administration of levodopa is associated with further hypometabolism in orbitofrontal cortex; an area known to be relevant for reversal learning where performance is typically impaired after dopaminergic treatment.
Copyright 2001 Movement Disorder Society.
Similar articles
-
Cortical glucose metabolism in Parkinson's disease without dementia.Neurobiol Aging. 1994 May-Jun;15(3):329-35. doi: 10.1016/0197-4580(94)90028-0. Neurobiol Aging. 1994. PMID: 7936057
-
Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease.J Cereb Blood Flow Metab. 2004 Jan;24(1):7-16. doi: 10.1097/01.WCB.0000092831.44769.09. J Cereb Blood Flow Metab. 2004. PMID: 14688612 Clinical Trial.
-
Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study.J Nucl Med. 2011 Jun;52(6):848-55. doi: 10.2967/jnumed.111.089946. Epub 2011 May 13. J Nucl Med. 2011. PMID: 21571793 Free PMC article.
-
[18F-fluorodeoxyglucose positron emission tomography in Parkinson's disease].Nihon Rinsho. 1997 Jan;55(1):222-6. Nihon Rinsho. 1997. PMID: 9014454 Review. Japanese.
-
Positron emission tomography imaging of regional cerebral glucose metabolism.Semin Nucl Med. 1986 Jan;16(1):2-34. doi: 10.1016/s0001-2998(86)80002-2. Semin Nucl Med. 1986. PMID: 2935938 Review.
Cited by
-
FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease.Neuroimage Clin. 2018 Aug 10;20:572-579. doi: 10.1016/j.nicl.2018.08.006. eCollection 2018. Neuroimage Clin. 2018. PMID: 30186761 Free PMC article.
-
Subthalamic nucleus stimulation affects limbic and associative circuits: a PET study.Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1512-20. doi: 10.1007/s00259-010-1436-y. Epub 2010 Mar 28. Eur J Nucl Med Mol Imaging. 2010. PMID: 20349231 Clinical Trial.
-
Spatiotemporal patterns of brain iron-oxygen metabolism in patients with Parkinson's disease.Eur Radiol. 2024 May;34(5):3074-3083. doi: 10.1007/s00330-023-10283-1. Epub 2023 Oct 19. Eur Radiol. 2024. PMID: 37853173
-
Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease.Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2737-50. doi: 10.1016/j.neubiorev.2013.09.008. Epub 2013 Oct 7. Neurosci Biobehav Rev. 2013. PMID: 24113323 Free PMC article. Review.
-
The Contribution of Type 2 Diabetes to Parkinson's Disease Aetiology.Int J Mol Sci. 2024 Apr 15;25(8):4358. doi: 10.3390/ijms25084358. Int J Mol Sci. 2024. PMID: 38673943 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical